Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701716 | Journal of Thoracic Oncology | 2017 | 26 Pages |
Abstract
Potentially targetable GAs in National Comprehensive Cancer Network NSCLC genes (30%) or intermediate or high TMB (43%, >10 mutations per Mb) were identified in most of the PSC cases. Thus, the use of comprehensive genomic profiling in clinical care may provide important treatment options for a historically poorly characterized and difficult to treat disease.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Alexa B. PhD, Shuyu D. PhD, Garrett M. PhD, James MD, Eduardo MD, Ranee MD, Steven C. DO, Jose A. MD, Nir MD, PhD, Nagla Abdel MD, PhD, K. Cynthia PhD, Manuel MD, James MD, Rong PhD, Sai-Hong Ignatius MD, PhD, Jeffrey S. MD, Philip J. PhD, Paul MD,